Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

The development of an immune response towards factor VIII (fVIII) remains a major complication for hemophilia A patients receiving fVIII infusions. The design of a specific therapy to restore unresponsiveness to fVIII has been hampered by the diversity of the anti-fVIII antibody. Molecular analysis of the specific immune response is therefore required. To this end, we have characterized an fVIII-specific human IgG4kappa monoclonal antibody (BO2C11) produced by a cell line derived from the memory B-cell repertoire of a hemophilia A patient with inhibitor. BO2C11 recognizes the C2 domain of fVIII and inhibits its binding to both von Willebrand factor (vWF) and phospholipids. It completely inhibits the procoagulant activity of native and activated fVIII, with a specific activity of approximately 7,000 Bethesda units/mg. vWF reduces the rate of fVIII inactivation by BO2C11. The antibody-fVIII association rate constant (kass approximately 7.4 x 10(5) M-1 s-1) is eightfold lower than that for vWF-fVIII association, whereas its dissociation rate constant (kdiss < or = 1 x 10(-5) s-1) is 100-fold lower than that for the vWF-fVIII complex, which suggests that BO2C11 almost irreversibly neutralizes fVIII after its dissociation from vWF. BO2C11 is the first human monoclonal anti-fVIII IgG antibody that has been isolated and allows the study of fVIII inactivation at the molecular level.

[1]  U. Hedner,et al.  Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. , 1993, Transfusion medicine reviews.

[2]  J. Arnout,et al.  Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. , 1993, Blood.

[3]  D. Voelker.  Adriamycin disrupts phosphatidylserine import into the mitochondria of permeabilized CHO-K1 cells. , 1991, The Journal of biological chemistry.

[4]  P. Lollar,et al.  Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. , 1991, The Journal of biological chemistry.

[5]  E. Saenko,et al.  A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by von Willebrand Factor (*) , 1995, The Journal of Biological Chemistry.

[6]  S. Shapiro,et al.  The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. , 1988, Blood.

[7]  C. Heirman,et al.  Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. , 1992, Blood.

[8]  J. Banchereau,et al.  Human B lymphocytes: phenotype, proliferation, and differentiation. , 1992, Advances in immunology.

[9]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[10]  G. E. Gilbert,et al.  Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.

[11]  L. Hoyer,et al.  The idiotypic characteristics of human antibodies to factor VIII. , 1984, Blood.

[12]  F E Preston,et al.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. , 1995, Blood.

[13]  L. Hoyer,et al.  Inactivation of factor VIII coagulant activity by two different types of human antibodies. , 1982, Blood.

[14]  J. Banchereau,et al.  Growing human B lymphocytes in the CD40 system , 1991, Nature.

[15]  L. Hoyer,et al.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. , 1989, The Journal of clinical investigation.

[16]  J. E. Curtis,et al.  Inhibition of human factor VIIIa by anti-A2 subunit antibodies. , 1994, The Journal of clinical investigation.

[17]  M. Shima,et al.  A Factor VIII Neutralizing Monoclonal Antibody and a Human Inhibitor Alloantibody Recognizing Epitopes in the C2 Domain Inhibit Factor VIII Binding to von Willebrand Factor and to Phosphatidylserine , 1993, Thrombosis and Haemostasis.

[18]  I. Sussman,et al.  STUDIES ON POSTTRANSFUSION AND DISSOCIATED FACTOR VIII AND IN PATIENTS WITH VON WILLEBRAND'S DISEASE , 1977 .

[19]  P. Lollar.  Analysis of Factor VIII Inhibitors Using Hybrid Human/Porcine Factor VIII , 1997, Thrombosis and Haemostasis.

[20]  J. Sixma,et al.  Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain. , 1987, European journal of biochemistry.

[21]  R. Houghten,et al.  Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. , 1990, Blood.

[22]  K. James,et al.  The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies to Human Procoagulant Factor VIII , 1986, Thrombosis and Haemostasis.

[23]  J. Ware,et al.  Analysis of structure-function relationships in the platelet membrane glycoprotein Ib-binding domain of von Willebrand's factor by expression of deletion mutants. , 1993, The Journal of biological chemistry.

[24]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.

[25]  J. V. van Mourik,et al.  The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII. , 1989, The Biochemical journal.

[26]  S. Ho,et al.  Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated. , 1996, Journal of immunology.

[27]  N. Klinman,et al.  In Vitro Analysis of the Generation and Propagation of Memory B Cells , 1996, Immunological reviews.

[28]  R. Biggs,et al.  The Treatment of Patients who have Factor‐VIII Antibodies , 1973, British journal of haematology.

[29]  C. Fulcher,et al.  Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G. Peltz,et al.  Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation. , 1988, Journal of immunology.

[31]  I. Brooks,et al.  Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. , 1993, Analytical biochemistry.

[32]  J. Vermylen,et al.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. , 1996, The Journal of clinical investigation.

[33]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[34]  F. Grieco,et al.  An improved procedure for the purification of protein fused with glutathione S-transferase. , 1992, BioTechniques.

[35]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[36]  R. Willemze,et al.  Proliferation of precursor B‐lineage acute lymphoblastic leukaemia by activating the CD40 antigen , 1996, British journal of haematology.

[37]  M. Shima,et al.  A role for the C2 domain of factor VIII in binding to von Willebrand factor. , 1994, The Journal of biological chemistry.

[38]  J. Roberts,et al.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Snow,et al.  A molecular-mechanics study of the conformation of the interchain disulfide of human immunoglobulin G4 (IgG4). , 1988, Molecular immunology.

[40]  J. Bloom.  The interaction of rDNA factor VIII, factor VIIIdes-797-1562 and factor VIIIdes-797-1562-derived peptides with phospholipid. , 1987, Thrombosis research.

[41]  K. Amano,et al.  Autoantibody to factor VIII that has less reactivity to factor Vlll/von Willebrand Factor Complex , 1995, American journal of hematology.

[42]  M. Kazatchkine,et al.  ANTI-IDIOTYPIC SUPPRESSION OF AUTOANTIBODIES TO FACTOR VIII (ANTIHAEMOPHILIC FACTOR) BY HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN , 1984, The Lancet.

[43]  R. Evans,et al.  Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors , 1991, British journal of haematology.

[44]  J. Thèze,et al.  Somatic diversification in the heavy chain variable region genes expressed by human autoantibodies bearing a lupus-associated nephritogenic anti-DNA idiotype. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E G Tuddenham,et al.  Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. , 1994, Nucleic acids research.

[46]  I. Sussman,et al.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. , 1977, The Journal of clinical investigation.

[47]  J. Sixma,et al.  Kinetics of Factor VIII-von Willebrand Factor Association , 1996 .

[48]  M. Shima,et al.  Common inhibitory effects of human anti‐C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor , 1995, British journal of haematology.

[49]  G. E. Gilbert,et al.  Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition* , 1996, The Journal of Biological Chemistry.

[50]  H. V. van Houwelingen,et al.  The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. , 1981, The New England journal of medicine.